BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Vorapaxar: Phase III discontinued

Merck said it is discontinuing vorapaxar in all 12,977 patients in the double-blind, placebo-controlled, international Phase III TRACER trial based on recommendations from a joint DSMB, but would not disclose additional details. The company said it has accumulated the predefined number of primary and major secondary endpoints even though not all of the patients...

Read the full 250 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >